Urology

A recent randomised trial evaluated the efficacy and safety of combination therapy in women with overactive bladder.

At 6 weeks, 65% of men achieve azoospermia, while 70–73% reach this milestone between weeks 10–16.

In women with recurrent UTIs, increasing water intake by 1500 mL daily reduced the number and frequency of infections.

Evidence from multiple studies and randomised controlled trials suggests that robot-assisted radical cystectomy delivers improved perioperative outcomes.

Real-world data underline that only a minority of patients complete the recommended 4–6 chemotherapy cycles.

Predictive biomarkers are expected to play a pivotal role in further enhancing treatment outcomes as they can identify patients at higher risk of recurrence.

A recent clinical trial explored the efficacy of combining pembrolizumab, an anti-PD-1 immunotherapy, with standard platinum-based chemotherapy.

Postoperative neurogenic bladder significantly impacts patients’ quality of life, necessitating prolonged catheter use in up to 16% of cases.